---
run_id: halo-evidence-vs-diagnosis-validation-v9-criteria-prompted-no-sources-06
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: criteria_prompted_no_sources
run_number: 6
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 606
prompt_source: condition packet (criteria_prompted_no_sources) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: an abstract evidence-quality criteria reminder, then the frozen Advisor prompt; no source names, source cards, or case-specific answer hint - see run-packet.md
source_packet_sha256: 99e91b34c6105209d4266fed0bcb0ab798bcedfae3a4ab5516c3c91fc972adaa
condition_packet_sha256: 99e91b34c6105209d4266fed0bcb0ab798bcedfae3a4ab5516c3c91fc972adaa
output_file: model-outputs/criteria_prompted_no_sources-06.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - criteria_prompted_no_sources (run 06)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `criteria_prompted_no_sources`, run 6 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 606, on the frozen condition packet.

## Output

**Recommendation: Run the Claim File Review.**

The current growth signals are contaminated by financial incentives (bundle pricing) and sales narratives (roadmap promises). Usage data is misleading because it captures manager-led demonstrations rather than adjuster-led productivity. The Claim File Review is the only intervention that isolates actual product utility from commercial pressure. By analyzing whether suggestions are accepted or overridden in a blind audit of existing files, you determine if the tool solves a problem or creates an administrative burden.

**Strongest reason against:**
This approach ignores the immediate commercial risk that the current expansion growth is a bubble. It does not test whether customers will pay for the product without discounts or roadmap promises, meaning you could validate that the tool is "useful" while remaining blind to the fact that it is not "marketable" at your current price point.

**Evidence that would change my mind:**
If the Commercial Cleanroom were modified to include a "forced-churn" analysis—specifically identifying if the two regional carriers who are already removing DraftPath did so because of a lack of utility or a lack of perceived value relative to price—I would switch to that. If the evidence shows that users *want* the tool but procurement is rejecting it, the problem is commercial; if they are rejecting it because it fails internal reviews (as seen in health-liability), the problem is the product.
